Home / Allogeneic CD5-specific CAR-T therapy for relapsedrefractory T-ALL: a phase 1 trial Allogeneic CD5-specific CAR-T therapy for relapsedrefractory T-ALL: a phase 1 trial unknow ★ 5.0 · 36 reads Sign in to save this Request CodeZLIB.IO18490975 Published2022 Pages1 LanguageUnknown